Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Sarcoma 1Genitourinary 1

Conditions

Renal Pelvis and Ureter Urothelial Carcinoma 1

Interventions

Gemcitabine 9Docetaxel 8Androgen Antagonists 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Magnetic Resonance Spectroscopy 6gallium 68 PSMA-11 5Prednisone 5Leuprolide 5Goserelin 5Cisplatin 5enzalutamide 4bicalutamide 4Triptorelin Pamoate 4Radiosurgery 4Carboplatin 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4luprolide acetate gel depot 3Flutamide 3Celecoxib 3valrubicin 2pembrolizumab 2nilutamide 2cabazitaxel 2abiraterone 2Zoledronic Acid 2Vinblastine 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × merphos × Genitourinary × Clear all
NCT04628767 2026-05-13

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

National Cancer Institute (NCI)

Phase 2/3 Recruiting
249 enrolled
Genitourinary

Renal Pelvis and Ureter Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡